growing population create a significant market opportunity. "Over the next 5 years, the Southeast Asian market is expected to grow with a compound annual growth rate of 11%, compared to about 7% for the US and Europe." There is a particular opportunity for generics because many small-molecule drugs and therapeutic proteins are unpatented in some regions. GeneMedix hopes that it will have a competitive advantage, as one of the few companies able to manufacture recombinant proteins in China.
However, despite an estimated $10 billion market for GeneMedix's products, investors have been cautious; GeneMedix's share price slipped from 90p to 77.5p the week following its listing.
One of the reasons could be that the company faces foreign-import competition from such companies as Immunex (Seattle, WA) and Cangene (Toronto/Winnipeg, Canada). In addition, John Langstaff, president and CEO of Cangene, says China is not a key territory for sales, arguing that many countries in Asia feel more confident about products that have been given the green light by western regulators such as the US FDA and the European Agency for the Evaluation of Medicinal Products. "Our view is that it is much easier to sell a product to a foreign country if you already have a license in the US or Europe." As a result, although Cangene has conducted clinical trials in China, Langstaff says that Cangene will focus on launching products in wealthier western markets.
In addition, GeneMedix's products may come under scrutiny as a source of exports: Not only must its Chinese manufacturing plant satisfy Western manufacturing standards, but the products will also have to meet whatever regulatory standards for biogenerics are agreed on by Western regulators. At present, these requirements are still being developed. Should GeneMedix launch its products in the US and Europe, it would also then have to battle with other western manufacturers-both smaller outfits and multinationals with generics businesses.
Liz Fletcher
Biogeneric manufacturer GeneMedix (Esher, UK) raised almost £20 million ($30 million) when it listed on the London and Singapore stock exchanges at the end of November. GeneMedix is the first biotechnology company to list in Singapore, attracted by the government's strong support of its blossoming life science sector and potential investor interest. However, other generic manufacturers are skeptical that GeneMedix, which plans to launch its first product in China, will be able to make an impact on the Southeast Asian market, given stiff competition from local manufacturers and the threat from foreign imports.
GeneMedix's listing on the London Stock Exchange was a natural step to take from an unregulated OFEX listing (an over-the-counter trading facility), but the move to the Singapore exchange was unusual. Kim Tan, one of GeneMedix founders, says that the company considered the option after being approached by the Singapore government. GeneMedix was impressed by the government's efforts to establish the island state as a regional hub for biotechnology and pharmaceutical businesses, in particular its commitment last year of S$1 billion (US$580 million) toward four investment funds to support R&D by life science companies. Whether investors will be equally supportive remains to be seen. However, Girish Sahajwalla, senior manager of corporate finance at PricewaterhouseCoopers in Singapore, says choosing Singapore makes sense. "While the sector is still young in Singapore, the government is promoting the life science industry and aims to establish Singapore as a biotechnology hub. . ."
GeneMedix plans to sell its first product-granulocyte macrophage colony-stimulating factor (GM-CSF), a treatment for patients with a low white blood cell countin China later this year. It has established a manufacturing facility near Shanghai through a joint venture with Shanghai Shenglanda Biotech (Shanghai) and, in July, it acquired 75% of the equity in Shanghai Dongxin Biotechnology, a subsidiary of the Chinese company. Through this deal, GeneMedix gets a high quality, but relatively low-cost, manufacturing facility in China; part of the proceeds of its initial public offering will fund this acquisition.
The Southeast asian markets, says Tan, are ripe for picking by drug manufacturers. Sahajwalla agrees that the market potential is significant, arguing that the increasing affluence and health consciousness of its
GeneMedix sets sights on Southeast Asia
The Chinese National State Planning Commission announced in November that it will invest RMB 200 million (US$ 24 million) over two years in the Beijing National Center for Biochip Design and Engineering (NCBDE). Observers think the effort, with its experienced director and focus on innovation, stands apart from most of the chipbased companies in China, many of which have arisen to cash in on the biochip frenzy in Asia.
The new center was set-up as a company in September 2000 jointly by Tsinghua University, the Chinese Academy of Medical Sciences, the Chinese Academy of Military Medical Sciences, and the Central China University of Science and Technology, all located in Beijing. It will receive RMB 25 million (US$ 3 million) per year from Tsinghua University, and RMB 5 million (US$ 600,000) from each of the other three institutions, and there are plans to raise another RMB 150 million (US$ 18.1 million) in venture capital from funds in Hong Kong, China, Malaysia, and the United States.
Some observers say chip-based technologies that are cheap and easy to handle could revolutionize medical care in China: State-of the-art diagnostic laboratories are highly centralized and concentrated in a few large cities, creating huge disparities in medical care infrastructure among the country's 1.25 billion population.
The center, which will focus research on "active" biochip technologies and microfluidic devices for applications in high-throughput screening and diagnos-
Chinese gov't chips in to industry
The financial district of Singapore, where GeneMedix is the first biotech firm to list.
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©Corbis ANALYSIS An English Court of Appeals decision in November held that Affymetrix (Santa Clara, CA) has a valid license to critical DNA microarray technology developed by Oxford Gene Technology (OGT; Oxford, UK). If upheld in the house of Lords, the UK's highest court, the decision effectively prohibits OGT from blocking Affymetrix from manufacturing and commercializing high-density GeneChips it develops using OGT technology. The news, which pushed share price of Affymetrix up 24.4% to $79.4, forces OGT to compete in the high-density microarray business with Affymetrix, which already holds 90% of a market estimated to be $527 million. However, although the decision could cost OGT millions in lost royalties, analysts say the decision will have no real impact on the chip industry as a whole, as newcomers move to alternative microarray systems.
The focal point of this transatlantic battle is a family of key US and European patents referred to as the "Southern patents" after their inventor, Edwin Southern, founder and majority owner of OGT, an Oxford University spinoff. Southern's patents, including US patents 5,700,637 ('637) and the newly issued 6,054,270 ('270)-not involved in this litigation-and their European counterparts, claim basic methods for creating and using arrays of oligonucleotides that are attached to solid supports such as a glass slide. The two patents cover methods of creating two types of microarrays: those formed by in situ synthesis of the probe oligonucleotides on the chip itself ('636)-a technology focused on in the Affymetrix litigation-and those created by deposition of oligonucleotides previously synthesized offline ('270). The two types of microarrays are widely used in the $2 billion genomics market to produce customized tools used in genotyping and diagnostic applications.
With OGT patents covering the general method of in situ hybridization of nucleic acids on a solid surface, and Affymetrix's patent estate including basic patents to the photolithographic method of synthesizing high-density array, it is clear companies wanting to enter this field need licenses for freedom to operate under these patents. "Affymetrix did not invent the array, yet they appear to be attempting to patent all arrays and achieve a monopoly over all arrays," says Southern. "This conduct may hinder the emergence of competitive array technologies, such as the computercontrolled printing techniques disclosed in our original filing. If not checked this could ultimately drive people away from arrays altogether."
Although Southern may be right about the microarray technology covered by his own patents and those held by Affymetrix, Robertson Stephens (New York) biotechnology analyst Ellen Lubman says that these legal challenges are more important for Affymetrix and OGT than for the chip industry as a whole. "Most companies entering the market are [now] developing tics, will have to compete with more than a dozen biochip companies set up in China over the past 1-2 years. These include Shangxi Super S&T, which in August started mass producing microarrays for the detection of genetic diseases; E-life Gene (Shenzen), which is developing hepatitis and cancer diagnostics; and BioWindow Gene Development (Shanghai), the only company with a commercially available cDNA array. "There has been a lot of interest in industry recently, and a number of large companies developing computer scanners or printers are presently considering whether to enter this field," says Konan Peck, who started work on cDNA microarrays at the Institute of Biomedical Science at the Academia Sinica in Taipei in late 1995. Although biochip R&D in Asia is still in its infancy and lags the US and UK, he says, the number of laboratories and companies in Taiwan, China, Korea, or Japan compares well with most European countries.
However, virtually all biochip companies and most of the thirty or so laboratories involved in biochip development in China are focused on DNA array fabrication using commercially available equipment imported from the US or Great Britain. The work being done on microarrays is now fairly standardized, says Larry Kricka, who directs research on analytical biochips at the University of Pennsilvania, "there are very few researchers in microfluidics in China."
The situation in China resembles that in Korea a year ago when, according to one observer, "any company that had 'biochip' in its name could easily launch an IPO, [independent] of whether they had much expertise, let alone a real product." The regional hype has arisen in part because many think the success of Asian economies in microelectronics and semiconductors can be easily translated into biotechnology. But most researchers working on biochip devices in China or Taiwan have entered the field only recently and, coming almost exclusively from an engineering background, often lack expertise in molecular biology and genetics. Aware of this, the Chinese government is now trying to entice Chinese scientists working with biochip startup companies in the US by "offering high salaries, hefty startup funds, and other benefits," says Peck.
Meanwhile, the new center, which aims to foster innovative research, is expected to be successful. It will be headed by Jing Cheng, who pioneered the development of laboratory-on-a-chip systems when working for San Diego, CA-based Nanogen (Nat. Biotechnol. 16, 541, 1998) . In addition to novel microfluiduics devices, the new center will also focus on cDNA libraries, databases, and bioinformatics tools. "We have an interesting technology that addresses front-end issues like sample preparation that many companies in the field are interested in," says Cheng, "we are not just looking at the Chinese market we are thinking globally."
Cheng, who is aware that "the amount of innovative and high quality work [in China] is fairly limited," was involved last year in founding Aviva Bioscience (San Diego) and ChipScreen Bioscience (Shenzen, near Hong Kong), both of which expect to start commercialization products within three to four years. Kricka says the work at Cheng's lab at Tsinghua University as well as at Aviva Bioscience-work that was presented at the 2000 International Forum on Biochip Technology in Beijing-is of very high quality. As for the new center, says Kricka, "I think what we see here is a country putting its efforts behind a technology in what is a major endeavor. . .This could well make China into a leader in the commercialization of analytical biochips."
Robert Triendl

Affymetrix license valid, rules court
China's chip shop. Chip-based technologies could revolutionize medical care in China.
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